The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Group-level narrow- and broad-band spectral changes after hemispherotomy reveal a marked EEG slowing of the isolated cortex, robust across patients. by Michele Angelo Colombo (22446342)

“…<p><b>(A)</b> The geometric mean of the PSD was taken first across electrodes, and subsequently across patients, for the observed PSD (main graph) as well as for the aperiodic fit of the PSD (corresponding to a straight line under logarithmic scale for both <i>x</i> and <i>y</i> axes, inset graph). …”

Five main steps of MATSim. by Jingfa Ma (20396406)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Effect sizes (if > 0.5) for the comparison of increasing load vs. decreasing for the iliocostalis muscle. by Christoph Anders (4068499)

Raw data of the main figures. by Masahiro Tomioka (430683)

Raw statistics of the main figures. by Masahiro Tomioka (430683)

The number of incidence, deaths and DALYs of AYAs with five main digestive cancers at global and regional level, 1990–2021. by Mengjia Zhu (15469202)

Effect sizes (if > 0.5) for the comparison of increasing load vs. decreasing load for the multifidus muscle. by Christoph Anders (4068499)

Effect sizes (if > 0.5) for the comparison of increasing load vs. decreasing load for the longissimus muscle. by Christoph Anders (4068499)

Map of Pakistan with marked Punjab province. by Sumaira Sumaira (21453523)

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Effect sizes (if > 0.5) for the comparison of increasing load vs. decreasing load for the rectus abdominis muscle. by Christoph Anders (4068499)

Effect sizes (if > 0.5) for the comparison of increasing load vs. decreasing load for the internal oblique muscle. by Christoph Anders (4068499)

Effect sizes (if > 0.5) for the comparison of increasing load vs. decreasing load for the external oblique muscle. by Christoph Anders (4068499)